Xandra Owens Breakefield, Ph.D.
This page shows the publications co-authored by Xandra Breakefield and Bob Carter.
Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro Oncol. 2017 Oct 19; 19(11):1494-1502.
Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells. Cancer Gene Ther. 2010 Sep; 17(9):655-63.
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008 Dec; 10(12):1470-6.
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv. 2018 03; 4(3):eaar2766.
Coding and noncoding landscape of extracellular RNA released by human glioma stem cells. Nat Commun. 2017 10 26; 8(1):1145.
Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium. J Extracell Vesicles. 2015; 4:26533.
Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun. 2015 May 11; 6:6999.
BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Mol Ther Nucleic Acids. 2013 Jul 23; 2:e109.
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012 Dec; 18(12):1835-40.
RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer. 2012 Jan 17; 12:22.
Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab Chip. 2010 Feb 21; 10(4):505-11.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.